Results

eNauka >  Results >  HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2t-argeting peptide vaccine plus SOC chemotherapy in patients with HER2+advanced stomach cancer - correlation of the antibody responses and clinical outcome
Title: HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2t-argeting peptide vaccine plus SOC chemotherapy in patients with HER2+advanced stomach cancer - correlation of the antibody responses and clinical outcome
Authors: Tobias, Joshua; Kundi, Michael; Garner-Spitzer, E; Zielinski, Christoph; Maglakelidze, Marina; Andric, Zoran G  ; Petrovic, Zeljko M; Nagarkar, R; Chawla, T; Chong, LMO;
Nixon, B; Yavrom, S; Ede, NJ; Wiedermann, Ursula;
Issue Date: 2023
Publication: ANNALS OF ONCOLOGY
ISSN: 0923-7534 Annals of Oncology Search Idenfier
Type: Conference Paper
Collation: vol. 34 str. S4-S4
DOI: 10.1016/j.annonc.2023.04.035
WoS-ID: 001037960400481
URI: https://enauka.gov.rs/handle/123456789/808000
Metadata source: (Preuzeto iz Nasi u WoS)
M-category: 
Mp. category will be shown later

4
WEB OF SCIENCETM
Altmetric
Dimensions
Unpaywall

Google ScholarTM

Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.